Notices. Notice
730 words·~3 min read·
/register/2000/09/06/00-22700A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4160-01-F DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket Nos. 00M-1215, 00M-1216, 00M-1228, 00M-1229, 00M-1230, 00M-1231, 00M-1298, 00M-1299, 00M-1300, 00M-1354] Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration
(FDA)is publishing a list of premarket applications
(PMA)that have been approved. This list is intended to inform the public of the availability of safety and effectiveness summaries of approved PMA's through the Internet and the agency's Dockets Management Branch. ADDRESSES: Summaries of safety and effectiveness are available on the Internet at http://www.fda.gov/cdrh/pmapage.html. Copies of summaries of safety and effectiveness are also available by submitting a written request to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Please cite the appropriate docket number as listed in table 1 in the Supplementary Information section of this document when submitting a written request. FOR FURTHER INFORMATION CONTACT: Thinh X. Nguyen, Center for Devices and Radiological Health (HFZ-402), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2186. SUPPLEMENTARY INFORMATION: In the **Federal Register** of January 30, 1998 (63 FR 4571), FDA published a final rule to revise §§ 814.44(d) and 814.45(d) (21 CFR 814.44(d) and 814.45(d)) to discontinue publication of individual PMA approvals and denials in the **Federal Register** . Instead, revised §§ 814.44(d) and 814.45(d) state that FDA will notify the public of PMA approvals and denials by posting them on the Internet on FDA's home page at http://www.fda.gov; by placing the summaries of safety and effectiveness on the Internet and in FDA's Dockets Management Branch; and by publishing in the **Federal Register** after each quarter a list of available safety and effectiveness summaries of approved PMA's and denials announced in that quarter. FDA believes that this procedure expedites public notification of these actions because announcements can be placed on the Internet more quickly than they can be published in the **Federal Register** , and FDA believes that the Internet is accessible to more people than the **Federal Register** . In accordance with section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360e(d)(3)), notification of an order approving, denying, or withdrawing approval of a PMA will continue to include a notice of opportunity to request review of the order under section 515(g) of the act. The 30-day period for requesting reconsideration of an FDA action under § 10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a PMA begins on the day the notice is placed on the Internet. Section 10.33(b) provides that FDA may, for good cause, extend this 30-day period. Reconsideration of a denial or withdrawal of approval of a PMA may be sought only by the applicant; in these cases, the 30-day period will begin when the applicant is notified by FDA in writing of its decision. The following is a list of approved PMA's for which summaries of safety and effectiveness were placed on the Internet in accordance with the procedure explained previously from April 1, 2000, through June 30, 2000. There were no denial actions during this period. The list provides the manufacturer's name, the product's generic name or the trade name, and the approval date. **Table** 1.— **List of Safety and Effectiveness Summaries for Approved PMA's Made Available April 1, 2000, through June 30, 2000** PMA Number/Docket No. Applicant Trade Name Approval Date P970054/00M-1216 Hogan & Hartson Biotrin Parvovirus B19 IGG EIA (V5191GUS). August 6, 1999 P970055/00M-1215 Hogan & Hartson Biotrin Parvovirus IGM EIA (V619IMUS). August 6, 1999 P980008/00M-1231 Lasersight Technologies, Inc. Laserscan LSX Excimer Laser System. November 12, 1999 P990009/00M-1229 Fusion Medical Technologies, Inc. Floseal Matrix/Floseal Matrix Hemostatic Sealant. December 8, 1999 H990008/00M-1228 Interpore Cross International. Telescopic Plate Spacer
(TPS)Spinal System. March 9, 2000 P990013/00M-1230 Starr Surgical Co. Collamer Single-Piece (Plate-Haptic) Ultraviolet Absorbing Posterior Chamber Intraocular Lens. April 2, 2000 P990048/00M-1300 Hogan & Hartson Zeiss Visulas 690 and Visulink PD T/900 Laser System. April 12, 2000 P990049/00M-1299 Coherent Medical Group Coherent Opal Photoactivator Laser System. April 12, 2000 P950020/00M-1298 Interventional Technologies.
(BSDB)PTCA Surgical Dilation Balloon. April 18, 2000 H99012/00M-1354 Cardiovascular Diagnostics, Inc. TAS Ecarin Clotting Time Test. May 11, 2000 Dated: August 10, 2000. Linda S. Kahan, Deputy Director for Regulations Policy, Center for Devices and Radiological Health. [FR Doc. 00-22700 Filed 9-5-00; 8:45 am]
Connectionstraces to 3
Traces to 3 documents
Citation graph
cites case law
Cites 3Cited by 0 across 0 sources